|
N/A
|
Colorectal Cancer Screening Tests |
82272
|
NCD 190.34
|
|
|
N/A
|
Cytopath, Pap Smear (Neopath Only) |
G0147
|
NCD 210.2
|
|
|
N/A
|
Cytopath, Pap Smear (Neopath & Manual Rescreen) |
G0148
|
NCD 210.2
|
|
|
N/A
|
Colorectal Cancer Screening Tests |
G0328
|
NCD 210.3
|
|
|
1ID
|
ID, Organism, Urine 1 |
87088
|
NCD 190.12
|
|
|
2ID
|
ID, Organism, Urine 2 |
87088
|
NCD 190.12
|
|
|
3ID
|
ID, Organism, Urine 3 |
87088
|
NCD 190.12
|
|
|
4ID
|
ID, Organism, Urine 4 |
87088
|
NCD 190.12
|
|
|
5ID
|
ID, Organism, Urine 5 |
87088
|
NCD 190.12
|
|
|
6ID
|
ID, Organism, Urine 6 |
87088
|
NCD 190.12
|
|
|
59R
|
VDRL, CSF Reflex to Titer |
86592
|
NCD 210.10
|
|
|
87
|
Chromosome Analysis, POC |
88233
88262
|
NCD 190.3
NCD 190.3
|
|
|
106
|
AFP Non-Maternal - Serum |
82105
|
NCD 190.25
|
|
|
142
|
Cholesterol |
82465
|
NCD 190.23
|
Yes82465 - When monitoring long-term anti-lipid dietary or pharmacologic therapy and when following patients with borderline high total or LDL cholesterol levels, it may be reasonable to perform the lipid panel annually. A lipid panel (CPT code 80061) at a yearly interval will usually be adequate while measurement of the serum total cholesterol or a measured LDL should suffice for interim visits if the patient does not have hypertriglyceridemia.
Any one component of the panel (CPT codes 82465, 83718 and 84478) or a measured LDL (CPT code 83721) may be reasonable and necessary up to six times the first year for monitoring dietary or pharmacologic therapy. More frequent total cholesterol HDL cholesterol, LDL cholesterol and triglyceride testing may be indicated for marked elevations or for changes to anti-lipid therapy due to inadequate initial patient response to dietary or pharmacologic therapy. The LDL cholesterol or total cholesterol may be measured three times yearly after treatment goals have been achieved.
Any one component of the panel (CPT codes 82465, 83718 and 84478) or a measured LDL may be reasonable and necessary up to six times the first year for monitoring dietary or pharmacologic therapy. More frequent total cholesterol HDL cholesterol, LDL cholesterol and triglyceride testing may be indicated for marked elevations or for changes to anti-lipid therapy due to inadequate initial patient response to dietary or pharmacologic therapy. The LDL cholesterol or total cholesterol may be measured three times yearly after treatment goals have been achieved.
|
|
172
|
Gamma GT |
82977
|
NCD 190.32
|
Yes82977 - When used to determine if other abnormal enzyme tests reflect liver abnormality rather than other tissue, it generally is not necessary to repeat a GGT more than one time per week.
|
|
176
|
Glucose |
82947
|
NCD 190.20
|
Yes82947 - In stable, non-hospitalized patients who are unable or unwilling to do home glucose monitoring, it may be reasonable and necessary to measure quantitative blood glucose up to 4 times annually. Depending on the age and condition of the patient, the type of diabetes, degree of control, and other co-morbid conditions, more frequent testing may be reasonable and necessary.
|
|
183
|
Chlamydia/GC, PCR |
87491
|
NCD 210.10
A58720
|
|
|
183
|
Chlamydia/GC PCR, Urine or Genital |
87591
|
NCD 210.10
A58720
|
|
|
189
|
HDL - Cholesterol |
83718
|
NCD 190.23
|
Yes83718 - When monitoring long-term anti-lipid dietary or pharmacologic therapy and when following patients with borderline high total or LDL cholesterol levels, it may be reasonable to perform the lipid panel annually. A lipid panel (CPT code 80061) at a yearly interval will usually be adequate while measurement of the serum total cholesterol or a measured LDL should suffice for interim visits if the patient does not have hypertriglyceridemia.
Any one component of the panel (CPT codes 82465, 83718 and 84478) or a measured LDL (CPT code 83721) may be reasonable and necessary up to six times the first year for monitoring dietary or pharmacologic therapy. More frequent total cholesterol HDL cholesterol, LDL cholesterol and triglyceride testing may be indicated for marked elevations or for changes to anti-lipid therapy due to inadequate initial patient response to dietary or pharmacologic therapy. The LDL cholesterol or total cholesterol may be measured three times yearly after treatment goals have been achieved.
Any one component of the panel (CPT codes 82465, 83718 and 84478) or a measured LDL may be reasonable and necessary up to six times the first year for monitoring dietary or pharmacologic therapy. More frequent total cholesterol HDL cholesterol, LDL cholesterol and triglyceride testing may be indicated for marked elevations or for changes to anti-lipid therapy due to inadequate initial patient response to dietary or pharmacologic therapy. The LDL cholesterol or total cholesterol may be measured three times yearly after treatment goals have been achieved.
|
|
200
|
Magnesium |
83735
|
A57189
|
|
|
202
|
Apolipoprotein A1 |
82172
|
A57037
|
|
|
203
|
Apolipoprotein B |
82172
|
A57037
|
|
|
207
|
CA15-3 |
86300
|
NCD 190.29
|
|
|
210
|
CA 19-9 |
86301
|
NCD 190.30
|
|
|
226
|
FTA-ABS |
86780
|
NCD 210.10
|
|
|
228
|
Triglycerides |
84478
|
NCD 190.23
|
Yes84478 - When monitoring long-term anti-lipid dietary or pharmacologic therapy and when following patients with borderline high total or LDL cholesterol levels, it may be reasonable to perform the lipid panel annually. A lipid panel (CPT code 80061) at a yearly interval will usually be adequate while measurement of the serum total cholesterol or a measured LDL should suffice for interim visits if the patient does not have hypertriglyceridemia.
Any one component of the panel (CPT codes 82465, 83718 and 84478) or a measured LDL may be reasonable and necessary up to six times the first year for monitoring dietary or pharmacologic therapy. More frequent total cholesterol HDL cholesterol, LDL cholesterol and triglyceride testing may be indicated for marked elevations or for changes to anti-lipid therapy due to inadequate initial patient response to dietary or pharmacologic therapy. The LDL cholesterol or total cholesterol may be measured three times yearly after treatment goals have been achieved.
|
|
231
|
Lipoprotein A |
83695
|
A57037
|
|
|
241
|
AFP Maternal, Screen - Serum |
82105
|
NCD 190.25
|
|
|
276
|
Iron Binding Capacity |
83540
83550
|
NCD 190.18
NCD 190.18
|
|
|
285
|
Tox - SAP 7AB |
80307
|
A55001
|
|
|
287
|
Iron, Total |
83540
|
NCD 190.18
|
|
|
348
|
CA 125 |
86304
|
NCD 190.28
|
|
|
355
|
Tox - SAP 5A |
80307
|
A55001
|
|
|
366
|
T4, Free |
84439
|
NCD 190.22
|
Yes84439 - Testing may be covered up to two times a year in clinically stable patients; more frequent testing may be reasonable and necessary for patients whose thyroid therapy has been altered or in whom symptoms or signs of hyper- or hypothyroidism are noted.
|
|
380
|
TSH |
84443
|
NCD 190.22
|
Yes84443 - Testing may be covered up to two times a year in clinically stable patients; more frequent testing may be reasonable and necessary for patients whose thyroid therapy has been altered or in whom symptoms or signs of hyper- or hypothyroidism are noted.
|
|
409
|
Lipoprotein ELP (Phenotype) |
82465
83700
84478
|
NCD 190.23
NCD 190.23
A57037
NCD 190.23
|
Yes82465 - When monitoring long-term anti-lipid dietary or pharmacologic therapy and when following patients with borderline high total or LDL cholesterol levels, it may be reasonable to perform the lipid panel annually. A lipid panel (CPT code 80061) at a yearly interval will usually be adequate while measurement of the serum total cholesterol or a measured LDL should suffice for interim visits if the patient does not have hypertriglyceridemia.
Any one component of the panel (CPT codes 82465, 83718 and 84478) or a measured LDL (CPT code 83721) may be reasonable and necessary up to six times the first year for monitoring dietary or pharmacologic therapy. More frequent total cholesterol HDL cholesterol, LDL cholesterol and triglyceride testing may be indicated for marked elevations or for changes to anti-lipid therapy due to inadequate initial patient response to dietary or pharmacologic therapy. The LDL cholesterol or total cholesterol may be measured three times yearly after treatment goals have been achieved.
Any one component of the panel (CPT codes 82465, 83718 and 84478) or a measured LDL may be reasonable and necessary up to six times the first year for monitoring dietary or pharmacologic therapy. More frequent total cholesterol HDL cholesterol, LDL cholesterol and triglyceride testing may be indicated for marked elevations or for changes to anti-lipid therapy due to inadequate initial patient response to dietary or pharmacologic therapy. The LDL cholesterol or total cholesterol may be measured three times yearly after treatment goals have been achieved.
Yes84478 - When monitoring long-term anti-lipid dietary or pharmacologic therapy and when following patients with borderline high total or LDL cholesterol levels, it may be reasonable to perform the lipid panel annually. A lipid panel (CPT code 80061) at a yearly interval will usually be adequate while measurement of the serum total cholesterol or a measured LDL should suffice for interim visits if the patient does not have hypertriglyceridemia.
Any one component of the panel (CPT codes 82465, 83718 and 84478) or a measured LDL may be reasonable and necessary up to six times the first year for monitoring dietary or pharmacologic therapy. More frequent total cholesterol HDL cholesterol, LDL cholesterol and triglyceride testing may be indicated for marked elevations or for changes to anti-lipid therapy due to inadequate initial patient response to dietary or pharmacologic therapy. The LDL cholesterol or total cholesterol may be measured three times yearly after treatment goals have been achieved.
|
|
410
|
Lipoprotein Metabolism Profile |
80061
82172
83700
|
NCD 190.23
A57037
NCD 190.23
A57037
|
Yes80061 - When monitoring long-term anti-lipid dietary or pharmacologic therapy and when following patients with borderline high total or LDL cholesterol levels, it may be reasonable to perform the lipid panel annually. A lipid panel (CPT code 80061) at a yearly interval will usually be adequate while measurement of the serum total cholesterol or a measured LDL should suffice for interim visits if the patient does not have hypertriglyceridemia.
Any one component of the panel (CPT codes 82465, 83718 and 84478) or a measured LDL (CPT code 83721) may be reasonable and necessary up to six times the first year for monitoring dietary or pharmacologic therapy. More frequent total cholesterol HDL cholesterol, LDL cholesterol and triglyceride testing may be indicated for marked elevations or for changes to anti-lipid therapy due to inadequate initial patient response to dietary or pharmacologic therapy. The LDL cholesterol or total cholesterol may be measured three times yearly after treatment goals have been achieved.
When monitoring long-term anti-lipid dietary or pharmacologic therapy and when following patients with borderline high total or LDL cholesterol levels, it may be reasonable to perform the lipid panel annually. A lipid panel (CPT code 80061) at a yearly interval will usually be adequate while measurement of the serum total cholesterol or a measured LDL should suffice for interim visits if the patient does not have hypertriglyceridemia.
Any one component of the panel (CPT codes 82465, 83718 and 84478) or a measured LDL may be reasonable and necessary up to six times the first year for monitoring dietary or pharmacologic therapy. More frequent total cholesterol HDL cholesterol, LDL cholesterol and triglyceride testing may be indicated for marked elevations or for changes to anti-lipid therapy due to inadequate initial patient response to dietary or pharmacologic therapy. The LDL cholesterol or total cholesterol may be measured three times yearly after treatment goals have been achieved.
|
|
415
|
Ferritin |
82728
|
NCD 190.18
|
Yes82728 - If a normal serum ferritin level is documented, repeat testing would not ordinarily be medically necessary unless there is a change in the patient's condition, and ferritin assessment is needed for the ongoing management of the patient. When an End Stage Renal Disease (ESRD) patient is tested for ferritin, testing more frequently than every three months (the frequency authorized by 3167.3, Fiscal Intermediary manual) requires documentation of medical necessity [e.g., other than Chronic Renal Failure (ICD-9-CM 585) or Renal Failure, Unspecified (ICD-9-CM 586)].
|
|
428
|
CEA |
82378
|
NCD 190.26
|
Yes82378 - Serum CEA determinations are generally not indicated more frequently than once per chemotherapy treatment cycle for patients with metastatic solid tumors which express CEA or every two months post-surgical treatment for patients who have had colorectal carcinoma. It may be proper to order the test more frequently when there has been a significant change from prior CEA level or a significant change in patient status which could reflect disease progression or recurrence. Testing with a diagnosis of an in situ carcinoma is not reasonably done more frequently than once, unless the result is abnormal, in which case the test may be repeated once.
|
|
434
|
Transferrin |
84466
|
NCD 190.18
|
|
|
437
|
Digoxin |
80162
|
NCD 190.24
|
|
|
449
|
TSH / T4, Free |
84439
84443
|
NCD 190.22
NCD 190.22
|
Yes84439 - Testing may be covered up to two times a year in clinically stable patients; more frequent testing may be reasonable and necessary for patients whose thyroid therapy has been altered or in whom symptoms or signs of hyper- or hypothyroidism are noted.
Yes84443 - Testing may be covered up to two times a year in clinically stable patients; more frequent testing may be reasonable and necessary for patients whose thyroid therapy has been altered or in whom symptoms or signs of hyper- or hypothyroidism are noted.
|
|
458
|
HLA-B27 |
86812
|
NCD 190.1
|
|
|
468P
|
HCG, Quant Pregnancy |
84702
|
NCD 190.27
|
Yes84702 - Not more than once per month for diagnostic purposes. As needed for monitoring of patient progress and treatment. Qualitative hCG assays (CPT 84703) are not appropriate for medically managing patients with known or suspected germ cell neoplasms.
|
|
468T
|
HCG, Quant, Tumor |
84702
|
NCD 190.27
|
Yes84702 - Not more than once per month for diagnostic purposes. As needed for monitoring of patient progress and treatment. Qualitative hCG assays (CPT 84703) are not appropriate for medically managing patients with known or suspected germ cell neoplasms.
|
|
471
|
Drugs of Abuse Screen (7 Panel), Meconium |
80307
|
A55001
|
|
|
479
|
Neisseria Gonorrhoeae PCR |
87591
|
NCD 210.10
A58720
|
|
|
479
|
GC, PCR |
87591
|
NCD 210.10
A58720
|
|
|
484
|
Chlamydia, PCR |
87491
|
NCD 210.10
A58720
|
|
|
484
|
Chlamydia Trachomatis PCR |
87491
|
NCD 210.10
A58720
|
|
|
495
|
Hepatitis B Surface Antigen |
87340
G0499
|
NCD 210.6
NCD 210.6
|
|
|
499
|
Hepatitis B Core Antibody, Total |
86704
G0499
|
NCD 210.6
NCD 210.6
|
|
|
500
|
Hepatitis B Surface Antibody |
86706
G0499
|
NCD 210.6
NCD 210.6
|
|
|
501
|
Hepatitis B Surface Ag, Confirmation |
87341
G0499
|
NCD 210.6
NCD 210.6
|
|
|
505
|
PSA, Total |
84153
|
NCD 190.31
|
Yes84153 - For patients with lower urinary tract signs or symptoms, total PSA is performed only once per year unless there is a change in the patient's medical condirtion. Medicare covers a screening total PSA test one each year for men over 50 years of age.
|
|
505
|
PSA, Total, Screen |
G0103
|
NCD 210.1
|
YesG0103 - Screening prostate specific antigen tests (PSA) are covered at a frequency of once every 12 months for men who have attained age 50. The test must be ordered by a beneficiary's attending physician, physician assistant, nurse practitioner, or clinical nurse specialist who is fully knowledgeable about the beneficiary's medical condition, and who would be responsible for using the results of the test in the overall management of the beneficiary's specific medical problem.
|
|
514
|
Prothrombin Time (PT) |
85610
|
NCD 190.17
|
Yes85610 - When an ESRD patient is tested for PT, testing more frequently than weekly requires documentation of medical necessity [e.g. other than Chronic Renal Failure (ICD-9-CM 585) or Renal Failure, Unspecified (ICD-9-CM 586)]. The need to repeat this test is determined by changes in the underlying medical condition and/or the dosing of warfarin. In a patient on stable warfarin therapy, it is ordinarily not necessary to repeat testing more than every two to three weeks.
|
|
516
|
Part. Throm. Time (PTT) |
85730
|
NCD 190.16
|
|
|
520
|
CBC w/o Diff |
85027
|
NCD 190.15
|
|
|
522
|
CBC w/Platelet Count |
85025
|
NCD 190.15
|
|
|
530
|
Eosinophil Count, Total |
85048
|
NCD 190.15
|
|
|
531
|
Magnesium, Urine |
83735
|
A57189
|
|
|
536
|
Hematocrit |
85014
|
NCD 190.15
|
|
|
537
|
Hemoglobin & Hematocrit |
85014
85018
|
NCD 190.15
NCD 190.15
|
|
|
538
|
Hemoglobin |
85018
|
NCD 190.15
|
|
|
542
|
Hepatitis C Antibody |
G0472
|
NCD 210.13
|
|
|
546
|
Platelet Count |
85049
|
NCD 190.15
|
|
|
564
|
White Blood Count |
85048
|
NCD 190.15
|
|
|
576
|
Platelet Aggregation |
85049
85576 x5
|
NCD 190.15
|
|
|
626C
|
Cath Urine Culture |
87086
|
NCD 190.12
|
|
|
626
|
Culture, Urine |
87086
|
NCD 190.12
|
|
|
695R
|
RPR, Reflex to Titer |
86592
|
NCD 210.10
|
|
|
701
|
Acetaminophen (Tylenol) |
G0480
|
A55001
|
|
|
725
|
Clinical Substance Abuse Panel 8A |
80307
|
A55001
|
|
|
808
|
Urine Drug Screen 12T |
80305
|
A55001
|
|
|
809
|
Tox - SAP 7 |
80307
|
A55001
|
|
|
810M
|
Urine Drug Screen, #2 (Medical) |
80307
|
A55001
|
|
|
811M
|
Drug Screen # 4 (Medical) |
80307
|
A55001
|
|
|
820
|
Urine Drug Screen, #2 (Medical) |
80307
|
A55001
|
|
|
877
|
Benzodiazepines, Urine Forensic Screen |
80307
|
A55001
|
|
|
879
|
Ethanol, Urine Forensic Screen |
80307
|
A55001
|
|
|
885
|
Clinical Substance Abuse Panel 5A |
80307
|
A55001
|
|
|
915
|
Lipid Panel |
80061
|
NCD 190.23
|
Yes80061 - When monitoring long-term anti-lipid dietary or pharmacologic therapy and when following patients with borderline high total or LDL cholesterol levels, it may be reasonable to perform the lipid panel annually. A lipid panel (CPT code 80061) at a yearly interval will usually be adequate while measurement of the serum total cholesterol or a measured LDL should suffice for interim visits if the patient does not have hypertriglyceridemia.
Any one component of the panel (CPT codes 82465, 83718 and 84478) or a measured LDL (CPT code 83721) may be reasonable and necessary up to six times the first year for monitoring dietary or pharmacologic therapy. More frequent total cholesterol HDL cholesterol, LDL cholesterol and triglyceride testing may be indicated for marked elevations or for changes to anti-lipid therapy due to inadequate initial patient response to dietary or pharmacologic therapy. The LDL cholesterol or total cholesterol may be measured three times yearly after treatment goals have been achieved.
When monitoring long-term anti-lipid dietary or pharmacologic therapy and when following patients with borderline high total or LDL cholesterol levels, it may be reasonable to perform the lipid panel annually. A lipid panel (CPT code 80061) at a yearly interval will usually be adequate while measurement of the serum total cholesterol or a measured LDL should suffice for interim visits if the patient does not have hypertriglyceridemia.
Any one component of the panel (CPT codes 82465, 83718 and 84478) or a measured LDL may be reasonable and necessary up to six times the first year for monitoring dietary or pharmacologic therapy. More frequent total cholesterol HDL cholesterol, LDL cholesterol and triglyceride testing may be indicated for marked elevations or for changes to anti-lipid therapy due to inadequate initial patient response to dietary or pharmacologic therapy. The LDL cholesterol or total cholesterol may be measured three times yearly after treatment goals have been achieved.
|
|
955
|
Cell Markers, 4 |
88184
88185 x3
88187
|
A57689
A57689
A57689
|
|
|
963
|
Cell Markers, 1 |
88184
|
A57689
|
|
|
967
|
Cell Markers, 5 |
88184
88185 x4
88187
|
A57689
A57689
A57689
|
|
|
968
|
Cell Markers, 6 |
88184
88185 x5
88187
|
A57689
A57689
A57689
|
|
|
971
|
T Helper-Inducer (CD4) |
86359
86361
|
A57689
A57689
|
|
|
974
|
Cell Markers, 8 |
88184
88185 x7
88187
|
A57689
A57689
A57689
|
|
|
975
|
Cell Markers, 9 |
88184
88185 x8
88187
|
A57689
A57689
A57689
|
|
|
976
|
Cell Markers, 10 |
88184
88185 x9
88187
|
A57689
A57689
A57689
|
|
|
977
|
Cell Markers, 11 |
88184
88185 x10
88187
|
A57689
A57689
A57689
|
|
|
979
|
Cell Markers, 12 |
88184
88185 x11
88187
|
A57689
A57689
A57689
|
|
|
981
|
Cell Markers, 13 |
88184
88185 x12
88187
|
A57689
A57689
A57689
|
|
|
982
|
Cell Markers, 14 |
88184
88185 x13
88187
|
A57689
A57689
A57689
|
|
|
983
|
Cell Markers, 15 |
88184
88185 x14
88187
|
A57689
A57689
A57689
|
|
|
985
|
Cell Markers, 16 |
88184
88185 x15
88187
|
A57689
A57689
A57689
|
|
|
986
|
Cell Markers, 7 |
88184
88185 x6
88187
|
A57689
A57689
A57689
|
|
|
989
|
Cell Markers, 17 |
88184
88185 x16
88187
|
A57689
A57689
A57689
|
|
|
990
|
Cell Markers, 18 |
88184
88185 x17
88187
|
A57689
A57689
A57689
|
|
|
1801
|
Acute Hepatitis Panel |
80074
|
NCD 190.33
|
Yes80074 - After a hepatitis diagnosis has been established, only individual tests, rather than the entire panel, are needed.
|
|
4008
|
GC/MS NIDA Lab |
80307
|
A55001
|
|
|
4024
|
Pap in Fld (Neopath Only) |
G0144
|
NCD 210.2
|
|
|
4025
|
Pap in Fld (Neopath - Manual Rescreen) |
G0145
|
NCD 210.2
|
|
|
4178
|
Tox - SAP 6 BO |
80307
|
A55001
|
|
|
4179
|
Tox - SAP 7 ABO |
80307
|
A55001
|
|
|
4182
|
HDL Cholesterol Subclasses |
83701
|
NCD 190.23
A57037
|
|
|
4183
|
Chlamydia Trachomatis, Culture |
87110
|
NCD 210.10
|
|
|
4191
|
Antidepressants Screen, Urine |
80307
|
A55001
|
|
|
4193
|
NMO/AQP4 IgG FACS Reflex to Titer |
86053
|
A57689
|
|
|
4283
|
B-Natriuretic Peptide |
83880
|
A57083
|
|
|
4292
|
Treponema Pallidum Ab CSF |
86780
|
NCD 210.10
|
|
|
4328
|
Chlamydia and GC, PCR |
87591
|
NCD 210.10
A58720
|
|
|
4328
|
Chlamydia/GC, PCR, SurePath/ThinPrep |
87491
|
NCD 210.10
A58720
|
|
|
4336
|
Chlamydia Trachomatis, PCR |
87491
|
NCD 210.10
A58720
|
|
|
4336
|
C. Trachomatis PCR, SurePath/ThinPrep |
87491
|
NCD 210.10
A58720
|
|
|
4337
|
N. Gonorrhoeae PCR, SurePath/ThinPrep |
87591
|
NCD 210.10
A58720
|
|
|
4337
|
Neisseria Gonorrhoeae, PCR |
87591
|
NCD 210.10
A58720
|
|
|
4367
|
Collagen Cross-Linked, NTX, 24 Hr Urine |
82523
|
NCD 190.19
|
Yes82523 - Current recommendations for appropriate utilization include: one or two base-line assays from specified urine collections on separate days; followed by a repeat assay about three months after starting anti-resorptive therapy; followed by a repeat assay in 12 months after the three-month assay; and thereafter not more than annually, unless there is a change in therapy in which circumstance an additional test may be indicated three months after the initiation of new therapy.
|
|
4391
|
Coenzyme Q10 |
82542
|
A55769
|
|
|
4539
|
Cell Markers, 2 |
88184
88185
88187
|
A57689
A57689
A57689
|
|
|
4540
|
Cell Markers, 3 |
88184
88185 x2
88187
|
A57689
A57689
A57689
|
|
|
4551
|
NIDA 5, GC/MS |
80307
|
A55001
|
|
|
4567
|
Factor V Leiden Mutation Analysis |
81241
|
A57423
|
|
|
4572
|
P, Spcl Stain Pas |
88313
|
|
|
|
4605
|
Ethanol, Clinical Urine |
80307
|
A55001
|
|
|
4609
|
HIV-1 RNA, Quant |
87536
|
NCD 190.13
A58720
|
Yes87536 - Measurement of plasma HIV RNA levels should be performed at the time of establishment of an HIV infection diagnosis. For an accurate baseline, 2 specimens in a 2-week period are appropriate.
|
|
4659
|
CA 27.29 |
86300
|
NCD 190.29
|
|
|
4682
|
Tox - SAP 6 NG |
80307
|
A55001
|
|
|
4686
|
Homocysteine, Total Serum |
83090
|
A57037
|
|
|
4700
|
Fructosamine |
82985
|
NCD 190.21
|
|
|
4710
|
T4, Free (Direct Dialysis) |
84439
|
NCD 190.22
|
Yes84439 - Testing may be covered up to two times a year in clinically stable patients; more frequent testing may be reasonable and necessary for patients whose thyroid therapy has been altered or in whom symptoms or signs of hyper- or hypothyroidism are noted.
|
|
4716
|
Meconium (Mec Stat-5) |
80307
|
A55001
|
|
|
4726
|
Tox - SAP 9A, GC/MS |
80307
|
A55001
|
|
|
4727
|
Tox - SAP 11A, GC/MS |
80307
|
A55001
|
|
|
4728
|
Tox - SAP 5, GC/MS |
80307
|
A55001
|
|
|
4729
|
Tox - SAP 10 |
80307
|
A55001
|
|
|
4730
|
Tox - SAP 11A |
80307
|
A55001
|
|
|
4731
|
Clinical Substance Abuse Panel 5 |
80307
|
A55001
|
|
|
4732
|
Clinical Substance Abuse Panel 7 |
80307
|
A55001
|
|
|
4733
|
Clinical Substance Abuse Panel 9A |
80307
|
A55001
|
|
|
4734
|
Clinical Substance Abuse Panel 10 |
80307
|
A55001
|
|
|
4735
|
Clinical Substance Abuse Panel 10A |
80307
|
A55001
|
|
|
4736
|
Clinical Substance Abuse Panel 11A |
80307
|
A55001
|
|
|
4737
|
Tox - SAP 10, GC/MS |
80307
|
A55001
|
|
|
4738
|
Tox - SAP 5A, GC/MS |
80307
|
A55001
|
|
|
4739
|
Tox - SAP 6, GC/MS |
80307
|
A55001
|
|
|
4740
|
Tox - SAP 7, GC/MS |
80307
|
A55001
|
|
|
4741
|
Tox - SAP 7A, GC/MS |
80307
|
A55001
|
|
|
4742
|
Tox - SAP 4, GC/MS |
80307
|
A55001
|
|
|
4779
|
Hemoglobin A1C |
83036
|
NCD 190.21
|
Yes83036 - It is not considered reasonable and necessary to perform glycated hemoglobin tests more often than every three months on a controlled diabetic patient to determine whether the patient's metabolic control has been on average within the target range. It is not considered reasonable and necessary for these tests to be performed more frequently than once a month for diabetic pregnant women. Testing for uncontrolled type one or two diabetes mellitus may require testing more than four times a year. Medical necessity documentation must support such testing in excess of the above guidelines.
|
|
4784
|
Comprehensive Urine Drug Screen |
80307
|
A55001
|
|
|
4839
|
P, Stain,Acid Fast |
88312
|
|
|
|
4869
|
P, Stain,Group 1 |
88312
|
|
|
|
4870
|
P, Stain,Group 2 |
88313
|
|
|
|
4875
|
Tissue - Stain, Immunoperoxidase |
88342
|
|
|
|
4880
|
P, Stain,Mast Cells X3 |
88313 x3
|
|
|
|
4910
|
Cell Markers, 19 |
88184
88185 x18
88187
|
A57689
A57689
A57689
|
|
|
4911
|
Cell Markers, 20 |
88184
88185 x19
88187
|
A57689
A57689
A57689
|
|
|
4912
|
Cell Markers, 21 |
88184
88185 x20
88187
|
A57689
A57689
A57689
|
|
|
4913
|
Cell Markers, 22 |
88184
88185 x21
88187
|
A57689
A57689
A57689
|
|
|
4915
|
Cocaine / Amphetamine Urine Screen |
80307
|
A55001
|
|
|
4923
|
Amphetamines, Clinical Urine |
80307
|
A55001
|
|
|
4924
|
Barbiturates, Clinical Urine |
80307
|
A55001
|
|
|
4925
|
Benzodiazepines, Clinical Urine |
80307
|
A55001
|
|
|
4926
|
Cocaine Metabolite |
80307
|
A55001
|
|
|
4927
|
Methadone, Clinical Urine |
80307
|
A55001
|
|
|
4928
|
Opiates, Clinical Urine |
80307
|
A55001
|
|
|
4929
|
Phencyclidine, Clinical Urine |
80307
|
A55001
|
|
|
4930
|
Propoxyphene, Clinical Urine |
80307
|
A55001
|
|
|
4931
|
THC, Clinical Urine |
80307
|
A55001
|
|
|
4960
|
Chlamydia & Chlamydophila Ab, IgG |
86631
|
NCD 210.10
|
|
|
4960
|
Chlamydia & Chlamydophila Ab, IgG |
86631
|
NCD 210.10
|
|
|
4961
|
Chlamydia & Chlamydophila Ab, IgM |
86632
|
NCD 210.10
|
|
|
4978
|
Collagen Cross-Linked, NTX, Random Urine |
82523
|
NCD 190.19
|
Yes82523 - Current recommendations for appropriate utilization include: one or two base-line assays from specified urine collections on separate days; followed by a repeat assay about three months after starting anti-resorptive therapy; followed by a repeat assay in 12 months after the three-month assay; and thereafter not more than annually, unless there is a change in therapy in which circumstance an additional test may be indicated three months after the initiation of new therapy.
|
|
4990
|
Vitamin D (1,25 Dihydroxy) |
82652
|
A57718
|
|
|
5047
|
JAK2 V617F Mutation Analysis |
81270
|
A57421
|
|
|
5078
|
IHC Morphometry |
88361
|
A57611
|
|
|
5088
|
HTLV I/II Ab, Western Blot |
86689
|
NCD 190.14
|
Yes86689 - If initial serologic tests are HIV EIA negative and there is no indication for confirmation of infection by viral RNA detection, the interval prior to retesting is 3-6 months.
|
|
5127
|
CT / NG RNA, TMA, Urogenital |
87491
|
NCD 210.10
A58720
|
|
|
5129
|
Cardio IQ Advanced Lipid Panel |
80061
83704
|
NCD 190.23
NCD 190.23
A57037
|
Yes80061 - When monitoring long-term anti-lipid dietary or pharmacologic therapy and when following patients with borderline high total or LDL cholesterol levels, it may be reasonable to perform the lipid panel annually. A lipid panel (CPT code 80061) at a yearly interval will usually be adequate while measurement of the serum total cholesterol or a measured LDL should suffice for interim visits if the patient does not have hypertriglyceridemia.
Any one component of the panel (CPT codes 82465, 83718 and 84478) or a measured LDL (CPT code 83721) may be reasonable and necessary up to six times the first year for monitoring dietary or pharmacologic therapy. More frequent total cholesterol HDL cholesterol, LDL cholesterol and triglyceride testing may be indicated for marked elevations or for changes to anti-lipid therapy due to inadequate initial patient response to dietary or pharmacologic therapy. The LDL cholesterol or total cholesterol may be measured three times yearly after treatment goals have been achieved.
When monitoring long-term anti-lipid dietary or pharmacologic therapy and when following patients with borderline high total or LDL cholesterol levels, it may be reasonable to perform the lipid panel annually. A lipid panel (CPT code 80061) at a yearly interval will usually be adequate while measurement of the serum total cholesterol or a measured LDL should suffice for interim visits if the patient does not have hypertriglyceridemia.
Any one component of the panel (CPT codes 82465, 83718 and 84478) or a measured LDL may be reasonable and necessary up to six times the first year for monitoring dietary or pharmacologic therapy. More frequent total cholesterol HDL cholesterol, LDL cholesterol and triglyceride testing may be indicated for marked elevations or for changes to anti-lipid therapy due to inadequate initial patient response to dietary or pharmacologic therapy. The LDL cholesterol or total cholesterol may be measured three times yearly after treatment goals have been achieved.
|
|
5141
|
Nicotine and Cotinine-Urine |
G0480
|
A55001
|
|
|
5143
|
Cardio IQ (R) LP-PLA2 Activity |
83698
|
A57037
|
|
|
5144
|
LP-PLA2 Activity |
83698
|
A57037
|
|
|
5147
|
C. Trachomatis, RNA, TMA, Urogenital |
87491
|
NCD 210.10
A58720
|
|
|
5171
|
Tox - SAP 5 LP, GC/MS |
80307
|
A55001
|
|
|
5174
|
T3 Uptake |
84479
|
NCD 190.22
|
Yes84479 - Testing may be covered up to two times a year in clinically stable patients; more frequent testing may be reasonable and necessary for patients whose thyroid therapy has been altered or in whom symptoms or signs of hyper- or hypothyroidism are noted.
|
|
5181
|
LGV Differential Antibody Panel |
86631 x8
86632 x4
|
NCD 210.10
NCD 210.10
|
|
|
5275
|
HIV-1 DNA, Qualitative, PCR |
87535
|
NCD 190.14
A58720
|
Yes87535 - If initial serologic tests are HIV EIA negative and there is no indication for confirmation of infection by viral RNA detection, the interval prior to retesting is 3-6 months.
|
|
5298
|
Neuron Specific Enolase (CSF) |
86316
|
A55028
|
|
|
5299
|
BCR-ABL Gene Rearrange, Qnt. Reflex |
81206
|
A57421
A58996
|
|
|
5324
|
Chlamydia & Chlamydophila Ab Panel |
86631 x6
88632 x3
|
NCD 210.10
|
|
|
5324
|
Chlamydia & Chlamydophila Ab Panel |
86631
|
NCD 210.10
|
|
|
5428
|
Prothrombin G20210A Mutation (Factor II) |
81240
|
A57423
|
|
|
5442
|
Hepatitis C RNA, Quant |
87522
|
A58720
|
|
|
5449
|
LDL-Cholesterol, Direct |
83721
|
NCD 190.23
A57037
|
Yes83721 - When monitoring long-term anti-lipid dietary or pharmacologic therapy and when following patients with borderline high total or LDL cholesterol levels, it may be reasonable to perform the lipid panel annually. A lipid panel (CPT code 80061) at a yearly interval will usually be adequate while measurement of the serum total cholesterol or a measured LDL should suffice for interim visits if the patient does not have hypertriglyceridemia.
Any one component of the panel (CPT codes 82465, 83718 and 84478) or a measured LDL (CPT code 83721) may be reasonable and necessary up to six times the first year for monitoring dietary or pharmacologic therapy. More frequent total cholesterol HDL cholesterol, LDL cholesterol and triglyceride testing may be indicated for marked elevations or for changes to anti-lipid therapy due to inadequate initial patient response to dietary or pharmacologic therapy. The LDL cholesterol or total cholesterol may be measured three times yearly after treatment goals have been achieved.
|
|
5461
|
CRP (High Sensitivity) |
86141
|
A57037
|
|
|
5469
|
Tox - SAP 5, GC/MS POC |
80307
|
A55001
|
|
|
5476
|
Tox - SAP 5, POC |
80307
|
A55001
|
|
|
5484
|
Tox - SAP 4 w/o THC, GC/MS |
80307
|
A55001
|
|
|
5509
|
Hepatitis B DNA, Quant |
87517
|
A58720
|
|
|
5531
|
T4, Total |
84436
|
NCD 190.22
|
Yes84436 - Testing may be covered up to two times a year in clinically stable patients; more frequent testing may be reasonable and necessary for patients whose thyroid therapy has been altered or in whom symptoms or signs of hyper- or hypothyroidism are noted.
|
|
5543
|
Tox - SAP 6 X |
80307
|
A55001
|
|
|
5544
|
Tox - SAP 11 X |
80307
|
A55001
|
|
|
5553
|
Collagen Type I C-Telopeptide |
82523
|
NCD 190.19
|
Yes82523 - Current recommendations for appropriate utilization include: one or two base-line assays from specified urine collections on separate days; followed by a repeat assay about three months after starting anti-resorptive therapy; followed by a repeat assay in 12 months after the three-month assay; and thereafter not more than annually, unless there is a change in therapy in which circumstance an additional test may be indicated three months after the initiation of new therapy.
|
|
5554
|
Platelet Morphology |
85008
|
NCD 190.15
|
|
|
5575
|
Clinical Substance Abuse Panel 11 E |
80307
|
A55001
|
|
|
5613
|
Cardio IQ Lipo Fractionation |
83704
|
NCD 190.23
A57037
|
|
|
5663
|
Cell Markers, 23 |
88184
88185 x22
88187
|
A57689
A57689
A57689
|
|
|
5664
|
Cell Markers, 24 |
88184
88185 x23
88187
|
A57689
A57689
A57689
|
|
|
5665
|
Cell Markers, 25 |
88184
88185 x24
88187
|
A57689
A57689
A57689
|
|
|
5666
|
Cell Markers, 26 |
88184
88185 x25
88187
|
A57689
A57689
A57689
|
|
|
5667
|
Cell Markers, 27 |
88184
88185 x26
88187
|
A57689
A57689
A57689
|
|
|
5674
|
Tox - SAP 5, GC/MS-DISC |
80307
|
A55001
|
|
|
5679
|
Vitamin D, 25-Hydroxy (D2 & D3) |
82306
|
A57718
|
YesFor frequency limitations, please review the "Indications and Limitations of Coverage" section within the Article and any associated LCD Policies indicated.
|
|
5691
|
Hepatitis BsAg w/Reflex to Confirmation |
87340
G0499
|
NCD 210.6
NCD 210.6
|
|
|
5774
|
NT proBNP |
83880
|
A57083
|
|
|
5778
|
Electrolyte & Osmolality Panel, Fecal |
83735
|
A57189
|
|
|
5808
|
HLA-B*5701 Typing |
81381
|
A57384
|
|
|
5823
|
Prostatitis Culture |
87086
|
NCD 190.12
|
|
|
5842
|
Chlamydia / GC TMA, Rectal |
87491
|
NCD 210.10
A58720
|
|
|
5843
|
CYP2C19 |
81225
|
A57384
|
|
|
5846
|
Chlamydia Trachomatis TMA, Throat |
87491
|
NCD 210.10
A58720
|
|
|
5847
|
Neisseria Gonorrhoeae TMA, Throat |
87591
|
NCD 210.10
A58720
|
|
|
5848
|
Chlamydia Trachomatis TMA, Rectal |
87491
|
NCD 210.10
A58720
|
|
|
5849
|
Neisseria Gonorrhoeae TMA, Rectal |
87591
|
NCD 210.10
A58720
|
|
|
5868
|
Clinical Substance Abuse Panel 8 Ox |
80307
|
A55001
|
|
|
5885
|
HPV, High Risk by PCR, Anal |
87624
|
A58720
|
|
|
5890
|
6-Acetylmorphine, Ur. Scrn, Clinical |
80307
|
A55001
|
|
|
5891
|
6-Acetylmorphine Ur. Scrn Forensic |
80307
|
A55001
|
|
|
5892
|
Hydrocodone, Ur. Scrn, Clinical |
80307
|
A55001
|
|
|
5893
|
Buprenorphine, Urine Screen |
80307
|
A55001
|
|
|
5898
|
Neisseria Gonorrhoeae, TMA, Urogenital |
87591
|
NCD 210.10
A58720
|
|
|
5984
|
Tox - SAP 6Ab, Intake |
80307
|
A55001
|
|
|
5986
|
Free PSA with Total PSA |
84153
|
NCD 190.31
|
Yes84153 - For patients with lower urinary tract signs or symptoms, total PSA is performed only once per year unless there is a change in the patient's medical condirtion. Medicare covers a screening total PSA test one each year for men over 50 years of age.
|
|
6177
|
Urorisk Diagnostic Profile |
83735
|
A57189
|
|
|
6185
|
MTHFR Mutation Analysis |
81291
|
A57423
|
|
|
6188
|
Stonerisk Diagnostic Profile |
83735
|
A57189
|
|
|
6191
|
Tox - SAP 9, GC/MS |
80307
|
A55001
|
|
|
6205
|
ZAP70 |
88184
88185
88187
|
A57689
A57689
A57689
|
|
|
6212
|
Magnesium, RBC |
83735
|
A57189
|
|
|
6234
|
Influenza type A and B, RT PCR |
87502
|
A58720
A59055
|
|
|
6255
|
Influenza A/B/RSV, RT PCR |
87502
87798
|
A58720
A59055
A55326
A58720
|
|
|
6421
|
B-Cell Lymph Leukemia Panel, FISH |
88271 x6
88275 x3
|
NCD 190.3
A57661
NCD 190.3
A57661
|
|
|
6422
|
Cystatin C |
82610
|
A57643
|
|
|
6423
|
Oxycodone, Clinical Urine |
80307
|
A55001
|
|
|
6424
|
Tox - Clinical SAP 6 OA |
80307
|
A55001
|
|
|
6425
|
Tox - Clinical SAP 8 OA |
80307
|
A55001
|
|
|
6426
|
Tox - Clinical SAP 10 OA |
80307
|
A55001
|
|
|
6427
|
Tox - Clinical SAP 11 OA |
80307
|
A55001
|
|
|
6556
|
Vitamin D, 25-Hydroxy, Total |
82306
|
A57718
|
YesFor frequency limitations, please review the "Indications and Limitations of Coverage" section within the Article and any associated LCD Policies indicated.
|
|
6557
|
Cell Markers, 28 |
88184
88185 x27
88187
|
A57689
A57689
A57689
|
|
|
6558
|
Cell Markers, 29 |
88184
88185 x28
88187
|
A57689
A57689
A57689
|
|
|
6559
|
Cell Markers, 30 |
88184
88185 x29
88187
|
A57689
A57689
A57689
|
|
|
6560
|
Cell Markers, 31 |
88184
88185 x30
88187
|
A57689
A57689
A57689
|
|
|
6561
|
Cell Markers, 32 |
88184
88185 x31
88187
|
A57689
A57689
A57689
|
|
|
6613
|
JAK2, V617F Mutation, Qual w/ Reflex Exon 12 |
81270
|
A57421
|
|
|
6614
|
JAK2 Exon 12 Mutation Analysis |
81403
|
A58679
|
|
|
6629
|
TPMT Genotype |
81335
|
A57384
|
|
|
6638
|
Tox - SAP 5 D, GC/MS |
80307
|
A55001
|
|
|
6648
|
Chromosome Analysis, Leukemic Blood |
88237
88264
|
NCD 190.3
NCD 190.3
|
|
|
6700
|
Dust / Mite Allergen Panel, IgE |
86003 x4
|
A57181
|
|
|
6701
|
Epithelia Allergen Panel, IgE |
86003 x6
|
A57181
|
|
|
6702
|
Grass Allergen Panel, IgE |
86003 x8
|
A57181
|
|
|
6703
|
Molds Allergen Panel, IgE |
86003 x13
|
A57181
|
|
|
6704
|
Meat Allergen Panel, IgE |
86003 x5
|
A57181
|
|
|
6705
|
Fish Allergen Panel, IgE |
86003 x7
|
A57181
|
|
|
6706
|
Shellfish Allergen Panel, IgE |
86003 x6
|
A57181
|
|
|
6707
|
Grain Allergen Panel, IgE |
86003 x6
|
A57181
|
|
|
6708
|
Fruit Allergen Panel, IgE |
86003 x6
|
A57181
|
|
|
6709
|
Legumes/Nuts Allergen Panel, IgE |
86003 x7
|
A57181
|
|
|
6710
|
Vegetable Allergen Panel, IgE |
86003 x14
|
A57181
|
|
|
6711
|
Other Food Allergen Panel, IgE |
86003 x6
|
A57181
|
|
|
6712
|
Venom Allergen Panel, IgE |
86003 x5
|
A57181
|
|
|
6714
|
Perennial Allergen Panel, IgE |
86003 x18
|
A57181
|
|
|
6715
|
Aeroallergen Allergy Panel, IgE |
86003 x21
|
A57181
|
|
|
6716
|
Food Allergy Profile (Phadia) |
86003 x12
|
A57181
|
|
|
6718
|
Hawaii Regional Respiratory Allergy Profile (Phadia) |
86003 x17
|
A57181
|
|
|
6719
|
Additional Respiratory Allergen Profile |
86003 x7
|
A57181
|
|
|
6723
|
Hawaii Regional Respiratory Allergy Panel |
86003 x25
|
A57181
|
|
|
6724
|
Food Allergy Panel |
86003 x15
|
A57181
|
|
|
6725
|
Infant Allergen Panel, IgE |
86003 x16
|
A57181
|
|
|
6734
|
Tox - Clinical SAP 10 XO |
80307
|
A55001
|
|
|
6736
|
Chromogranin A |
86316
|
A55028
|
|
|
6737
|
MDMA (Ecstacy), Urine Screen |
80307
|
A55001
|
|
|
6738
|
Cytopath, Thin Prep & Manual Screen |
G0123
|
NCD 210.2
|
|
|
7010
|
Celiac Disease Genotyping |
81376
81383
|
A57970
A57384
A57441
|
|
|
7025
|
KRAS Mutation Analysis |
81275
|
A54498
|
|
|
7026
|
BRAF Mutation Analysis |
81210
|
A54418
|
|
|
7027
|
EGFR Mutation Analysis |
81235
|
A54422
|
|
|
7028
|
NTRK NGS Fusion Profile |
81479
|
A57901
|
|
|
7029
|
Pan-TRK |
88342
|
|
|
|
7034
|
ROS1 |
88342
|
|
|
|
7120
|
Comprehensive Drug Screen, Serum |
80307
|
A55001
|
|
|
7136
|
HLA-A,B,C,DR,DQ, Renal |
81370
|
A57970
|
|
|
7137
|
HLA-A,B,C,DR,DQA,DQB,DP Deceased |
81370
81376
|
A57970
A57970
|
|
|
7139
|
HLA A,B Typing (Platelet Refractory) |
86813
|
NCD 190.1
|
|
|
7140
|
HLA-A,B,C,DR,DQ Typing (TRALI) |
81370
|
A57970
|
|
|
7148
|
HLA-C |
81373
|
A57970
|
|
|
7151
|
HLA-DQB |
81376
|
A57970
|
|
|
7162
|
Chlamydia / GC TMA, Throat |
87491
|
NCD 210.10
A58720
|
|
|
7169
|
Immunodeficieny Panel 1 Profile |
86355
86359
86360
|
A57689
A57689
A57689
|
|
|
7170
|
Immunodeficieny Panel 2 Profile |
86355
86357
86359
86360
|
A57689
A57689
A57689
A57689
|
|
|
7172
|
T Cell Subset Panel (T4/T8 Ratio) |
86359
86360
|
A57689
A57689
|
|
|
7176
|
Total B Cells Profile |
86355
|
A57689
|
|
|
7177
|
CD20 + B Cells Profile |
86355
86356
|
A57689
A57689
|
|
|
7178
|
Natural Killer Cells Profile |
86357
|
A57689
|
|
|
7188
|
SAP 4 GC/MS, Ref |
80307
|
A55001
|
|
|
7189
|
SAP 10 GC/MS, Ref |
80307
|
A55001
|
|
|
7194
|
Synthetic Cannabinoid Metab., Urine |
80307
|
A55001
|
|
|
7206
|
NGS Oncology Tumor Profile (Tissue only) |
81479
|
A57901
|
|
|
7207
|
NGS Oncology Melanoma Profile (Tissue Only) |
81445
|
A57901
A58454
A58973
|
|
|
7212
|
Pneumonia Panel by Filmarray |
87632
|
A58720
|
|
|
7220
|
Ethyl Glucuronide, Urine Screen |
80307
|
A55001
|
|
|
7221
|
Tox - SAP 7A, Intake |
80307
|
A55001
|
|
|
7612
|
NGS Target Oncology Mutation Panel |
81445
|
A57901
A58454
A58973
|
|
|
7613
|
NGS Oncology Melanoma Profile |
81445
88381
|
A57901
A58454
A58973
|
|
|
7614
|
HPV |
87624
|
A58720
|
|
|
7619
|
B-CELL UNLISTED MOLECULAR PATHOLOGY, TISSUE |
81479
|
|
|
|
7620
|
Synthetic Cannabinoids Screen, Blood |
80307
|
A55001
|
|
|
7631
|
Pap Smear w/ Reflex to HPV |
G0476
|
NCD 210.2.1
|
|
|
7631
|
PAP and HPV Co-Testing |
87624
|
A58720
|
|
|
7641
|
BRAF Mutation Analysis |
81210
|
A54418
|
|
|
7642
|
EGFR Mutation Analysis |
81235
|
A54422
|
|
|
7654
|
KRAS Mutation Analysis |
81275
|
A54498
|
|
|
7659
|
Lung NGS Fusion Profile |
81445
|
A57901
A58454
A58973
|
|
|
7662
|
NRAS Mutation Analysis |
81403
81311
|
A58679
A57486
|
|
|
7674
|
Calreticulin Mutation Analysis |
81219
|
A57421
|
|
|
7707
|
HPV High Risk PCR 16/18 Genotype |
87624
|
A58720
|
|
|
7710
|
Ethyl Glucuronide, Random Urine |
80307
|
A55001
|
|
|
7748
|
Lymphocyte Subset Panel 1 |
86355
86357
86359
86360
|
A57689
A57689
A57689
A57689
|
|
|
7760
|
HIV-1/2 Ag/Ab Screen with Reflex |
G0475
|
NCD 210.7
|
|
|
7760
|
HIV-1/2 Ag/Ab Screen with Reflex |
86701
86702
87390
|
NCD 190.14
NCD 190.14
NCD 190.14
|
Yes86701 - If initial serologic tests are HIV EIA negative and there is no indication for confirmation of infection by viral RNA detection, the interval prior to retesting is 3-6 months.
Yes86702 - If initial serologic tests are HIV EIA negative and there is no indication for confirmation of infection by viral RNA detection, the interval prior to retesting is 3-6 months.
Yes87390 - If initial serologic tests are HIV EIA negative and there is no indication for confirmation of infection by viral RNA detection, the interval prior to retesting is 3-6 months.
|
|
7766
|
MOG-IgG1 FACS, Serum |
86363
|
A57689
|
|
|
7860
|
APOE Genotyping Alzheimer Risk |
81401
|
A57384
A58996
|
|
|
7862
|
APOE Genotyping Cardiovascular Risk |
81401
|
A57384
A58996
|
|
|
7933
|
CNS Demyelinating Disease Evaluation, Serum |
86053
86363
|
A57689
A57689
|
|
|
7960
|
Chromosome Analysis, Blood |
88230
88262
|
NCD 190.3
NCD 190.3
|
|
|
7984
|
Chromosome Analysis Amniotic Fluid |
88235
88269
88280
88285
|
NCD 190.3
NCD 190.3
NCD 190.3
NCD 190.3
|
|
